AstraZeneca PLC logo

AstraZeneca (AZN) stock

AZN · AstraZeneca PLC · NYSE

$174.42-0.94 (-0.54%)today
Website
Market cap
$270.48B
Shares out
1.55B
Open
$176.22
Prev close
$175.36
VWAP
$175.98
52-week range69% up the range
$89.04$212.68

Today $174.07 - $177.41

What is the latest news on AZN stock?

AZN fell 0.54% to $174.42 on Nov 20, 2026. No AZN story in the last two days; the most recent is below.

PRago
Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers

Based on CLARITY-Gastric01 Phase III trial results which showed Sone-Ve reduced the risk of death by 42% in this settingConsistent Sone-Ve efficacy data across CLDN18.2 expression levels (>25%) supports potential use in up to 60% of patients in this settingAstraZeneca’s Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma (EAC) with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumor cells at any staining intensity.The Food and Drug Administratio

All AZN news
Price$174.42+9.85 (+5.99%)
2026-08-202026-11-20

When does AstraZeneca report earnings?

The latest AstraZeneca earnings release came out on Oct 30, 2026: AstraZeneca results: 9M and Q3 2026. Before that, AstraZeneca reported on Jul 27, 2026 and Apr 29, 2026. On that schedule the next report would come around late January 2027.

AZN earnings history

Are insiders buying or selling AZN?

Insiders are buying. In the last 90 days 1 insider bought $3K of AZN in trades reported on Form 4. The latest: Mani Sharma bought $3K, reported on Sep 11, 2026.

AZN insider trades

Financial highlights

Full financials
Revenue, FY2025
$58.74B
Revenue growth
+8.6%
Net income, FY2025
$10.22B
Net margin
17.4%
Free cash flow, FY2025
$11.77B
Cash
$5.71B

For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.

Latest news

25 items

Hiring

Nov 22, 2026

AstraZeneca PLC lists 859 open roles on its careers site as of Nov 22, 2026.

Open roles
859

Counted daily from AstraZeneca PLC's careers site.

AZN rankings

News · 26 weeks120-45%
2026-05-31: 52026-06-07: 12026-06-14: 22026-06-21: 32026-06-28: 72026-07-05: 32026-07-12: 22026-07-19: 22026-07-26: 72026-08-02: 42026-08-09: 02026-08-16: 82026-08-23: 52026-08-30: 102026-09-06: 62026-09-13: 92026-09-20: 42026-09-27: 82026-10-04: 62026-10-11: 02026-10-18: 52026-10-25: 112026-11-01: 22026-11-08: 52026-11-15: 52026-11-22: 0
2026-05-312026-11-22
Mix7690d
  • Other37(49%)
  • SEC Filings32(42%)
  • Insider3(4%)
  • Analyst2(3%)
  • Offering1(1%)
  • Earnings1(1%)
Activity · 52 weeks236116 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Our reporting on AZN

AstraZeneca PLC (AZN) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 25 wire items for AZN, including 15 press releases and news items, 8 SEC filings and 1 earnings update. The most recent was published Nov 19, 2026.

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN FAQ

12 questions
  • What does AstraZeneca PLC do?
    AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir...
  • What is AZN revenue?
    AstraZeneca PLC (AZN) reported $58.74B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 8.6% from the year before.
  • Is AZN profitable?
    Yes. AstraZeneca PLC earned $10.22B in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 17.4%.
  • How much cash and debt does AZN have?
    AstraZeneca PLC reported $5.71B in cash and cash equivalents and $27.82B of debt on its most recent balance sheet in SEC filings.
  • Is AstraZeneca PLC (AZN) hiring?
    AstraZeneca PLC lists 859 open roles on its careers site as of Nov 22, 2026.
  • Where does AZN stock trade?
    AstraZeneca PLC (AZN) is listed on NYSE.
  • What sector and industry is AZN in?
    AstraZeneca PLC operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did AstraZeneca PLC go public?
    AstraZeneca PLC (AZN) completed its IPO in 2026.
  • Does AZN pay a dividend?
    AZN's most recent ex-dividend date was 2026-08-07 with a cash dividend of $1.06 per share. No future ex-date is on file yet.
  • What are analysts saying about AZN?
    Across the last 8 analyst actions on AstraZeneca PLC, there were 2 upgrades and 2 downgrades. The most recent action was from Deutsche Bank: Hold on 2026-09-15. Recent price targets cluster around $75.00.
  • What companies are similar to AZN?
    Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), SNY (Sanofi), PFE (Pfizer Inc.), LLY (Eli Lilly and Company). Compare AZN side-by-side with any of them on Quantisnow.
  • How can I track AZN on Quantisnow?
    Quantisnow aggregates AstraZeneca PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZN to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change